We are live on ! Find out more

InflaRx

IFRX

Market cap $218M

1.48 USD

-0.14

8.64%

At close Updated Nov 4, 4:00 PM EST

Pre-market

After hours

1.45

-0.03

2.03%

1 day

-8.64%

5 days

-14.94%

1 month

-11.9%

3 months

-16.85%

6 months

-30.52%

Year to date

35.78%

1 year

16.54%

5 years

-68.44%

10 years

-90.13%

About: InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Employees: 65

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

InflaRx N.V. (IFRX) Analyst/Investor Day Transcript

InflaRx N.V. ( IFRX ) Analyst/Investor Day November 3, 2026 8:00 AM EST Company Participants Jan Medina - Head of Investor Relations & VP Niels Riedemann - Co-Founder, CEO & Executive Director Thomas Taapken - Chief Financial Officer Conference Call Participants Jörg Köhl Peter Merkel Yatin Suneja - Guggenheim Securities, LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Mazahir Alimohamed - Oppenheimer & Co. Inc., Research Division Joseph Stringer - Needham & Company, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Presentation Jan Medina Head of Investor Relations & VP Ladies and gentlemen, good morning, and thank you for standing by, and thank you for joining the InflaRx Capital Markets event to discuss the evolving treatment landscape and unmet need in AAV as well as our development strategy for izicopan in AAV and other renal indications.

InflaRx N.V. (IFRX) Analyst/Investor Day Transcript

InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials

InflaRx NASDAQ: IFRX outlined plans to advance its oral C5a receptor antagonist izicopan in ANCA-associated vasculitis (AAV), with an initial focus on patients with kidney involvement and a parallel study intended to evaluate corticosteroid reduction.

InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028 Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroids Initial data from an investigator-initiated open-label pilot study in atypical hemolytic uremic syndrome (aHUS) anticipated in the second half of 2027 InflaRx planning pilot study in IgA nephropathy (IgAN) to be initiated in 2027, with expected early data readout in 2028 InflaRx announces Advisory Board comprised of leading international experts in vasculitis, nephrology and immune-mediated renal disease InflaRx proprietary research indicates izicopan's product profile supports the potential for significant AAV market expansion, with an estimated peak sales potential in the range of $1.5 - 2.0 billion BDB-001, a vilobelimab cell line-produced antibody targeting C5a and being evaluated by InflaRx's collaborator, Staidson BioPharmaceuticals Co., Ltd. (Staidson), is currently in a Phase 3 trial in AAV in China, with data anticipated in 2H 2028 Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, expected to fund ongoing operations and clinical development through 2029 Jena, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V.

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

InflaRx Announces November Investor Events

Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.

InflaRx Announces November Investor Events

InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026

Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases.

InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026.

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

InflaRx to Host Virtual Capital Markets Day

Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.

InflaRx to Host Virtual Capital Markets Day

InflaRx Announces Participation in September Investor Conferences

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:

InflaRx Announces Participation in September Investor Conferences

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&I) indications Virtual Capital Markets Day planned for October 8, 2026 in the morning ET Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, including net proceeds from the underwritten public offering completed in May, expected to fund ongoing operations and clinical development through 2029 Jena, Germany, Aug. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced financial results for the three months ended June 30, 2026, and provided a business update.

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

See News Rankings

Price charts implemented using Lightweight Charts™